Silodosin
FDA-approved product (capsule, oral), marketed as Rapaflo, Silodosin.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Benign prostatic hyperplasia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Alpha-adrenoreceptor antagonists
- FDA pharmacologic class
- alpha-Adrenergic Blocker FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA44.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli41.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae29.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis56.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Silodosin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Trimetrexate GlucuronateExisting use: Other agents against amoebiasis and other protozoal diseases88.6% AI-predicted activityagainst E. coliLab records exist17 registered studies
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more87.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more86.8% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more82.2% AI-predicted activityagainst E. coli44 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives81.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Leucovorin CalciumExisting use: Osteosarcoma67.6% AI-predicted activityagainst E. coli50+ registered studies
- LevoleucovorinExisting use: Anemia, Colorectal adenocarcinoma, Colorectal cancer and 3 more67.6% AI-predicted activityagainst E. coli50+ registered studies
- PyrimethamineExisting use: Malaria, Toxoplasmosis64.6% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Copanlisib DihydrochlorideExisting use: Follicular lymphoma, Neoplasm, Neoplasm of mature B-cells63.5% AI-predicted activityagainst E. coli10 registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria62.6% AI-predicted activityagainst E. coli23 registered studies
- Rimegepant SulfateExisting use: Migraine disorder61.6% AI-predicted activityagainst E. coli50+ registered studies
- Histrelin AcetateExisting use: Neoplasm, Prostate adenocarcinoma, Prostate cancer61.6% AI-predicted activityagainst E. coli13 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
NCT00224133 · start 2005-09
Registered record
- Registry ID
- NCT00224133
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Silodosin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-09
- Completion
- 2007-04
- Enrolment
- 661
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic HyperplasiaInterventionSilodosinPhasePhase 3Registry statusCompletedA New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
NCT00224107 · start 2005-05
Registered record
- Registry ID
- NCT00224107
- Conditions
- Benign Prostatic Hyperplasia (BPH)
- Interventions
- Silodosin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-05
- Completion
- 2006-08
- Enrolment
- 461
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic Hyperplasia (BPH)InterventionSilodosin; PlaceboPhasePhase 3Registry statusCompletedA New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
NCT00224120 · start 2005-05
Registered record
- Registry ID
- NCT00224120
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Silodosin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-05
- Completion
- 2006-05
- Enrolment
- 462
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic HyperplasiaInterventionSilodosin; PlaceboPhasePhase 3Registry statusCompletedA Comparative Study of KSO-0400 in BPH Patients With LUTS
NCT01222650
Registered record
- Registry ID
- NCT01222650
- Conditions
- Benign Prostatic Hyperplasia (BPH)
- Interventions
- KSO-0400; KSO-0400; Silodosin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 400
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic Hyperplasia (BPH)InterventionKSO-0400; KSO-0400; Silodosin; PlaceboPhasePhase 2Registry statusCompletedA Dose-finding Study of Silodosin in Patients With Urinary Calculi
NCT01539265
Registered record
- Registry ID
- NCT01539265
- Conditions
- Urinary Calculus
- Interventions
- silodosin; silodosin; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 300
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUrinary CalculusInterventionsilodosin; silodosin; placeboPhasePhase 2Registry statusCompleted